The Feasibility Of Modified Paclitaxel-eluting Polymer-coated Stent Manufactured In China For Prevention Of Restenosis In Porcine Artery Coronary Model

Restenosis due to overhealing after percutaneous coronary revascularization was the biggest obstacle of advance of percutaneous coronary intervention (PCI) in the late 25 years. When stents reduce the restenosis rate to 15-30%, in-stent restenosis (ISR) caused primarily by neointimal hyperplasia still exists. Drug-eluting stent enable to deliver the drag which can intervene pathological process of restenosis to target lesion locally, its effects of prevention ISR have been proved by many animal and clinical studies. Paclitaxel, a microtubule-stabling compound, is one of these agents. But paclitaxel stent named as TAXUS stent has a problem with drug releasing model, that is only less than 10% of drug is released in the first 10 days and about 90% remains in the polymer. Nobody knows the long-term effects of the residual drags remained...